← All trials
NCT04762992
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Dec 30, 2024
- Completion date
- Jul 30, 2025
- First posted
- Feb 21, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centro Hospitalar de Lisboa CentralLead sponsor
- Centro Hospitalar de Lisboa CentralStudy chair
- Centro Hospitalar de Lisboa CentralOverall official - principal investigator
- University of PortoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.